Disease · MONDO_0018874
Comparisons in its trials448
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 448
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SGI-110 (Guadecitabine) vs Treatment Choice: Number of Participants With Composite CR (CRc) | 93 of 408 | 91 of 407 | 815 | NCT02348489 | Trial comparisons |
| SGI-110 (Guadecitabine) vs Treatment Choice: Number of Participants With a Complete Response (CR) | 79 of 408 | 71 of 407 | 815 | NCT02348489 | Trial comparisons |
| SGI-110 (Guadecitabine) vs Treatment Choice: deaths from any cause | 341 of 408 | 344 of 407 | 815 | NCT02348489 | Trial comparisons |
| SGI-110 (Guadecitabine) vs Treatment Choice: serious adverse events | 327 of 401 | 297 of 392 | 793 | NCT02348489 | Trial comparisons |
| Induction and Consolidation Chemotherapy Plus Midostaurin vs Induction and Consolidation Chemotherapy Plus Placebo: serious adverse events | 157 of 355 | 154 of 354 | 709 | NCT00651261 | Trial comparisons |
| Group A (Vosaroxin/Cytarabine) vs Group B (Placebo/Cytarabine): deaths from any cause | 273 of 355 | 288 of 350 | 705 | NCT01191801 | Trial comparisons |
| Group A (Vosaroxin/Cytarabine) vs Group B (Placebo/Cytarabine): serious adverse events | 197 of 355 | 125 of 350 | 705 | NCT01191801 | Trial comparisons |
| Standard Daunorubicin (Induction Therapy) vs High Dose Daunorubicin (Induction Therapy): serious adverse events | 328 of 328 | 325 of 325 | 653 | NCT00049517 | Trial comparisons |
| Ara-C+Daunomycin vs Ara-C+Daunomycin+Mylotarg: Complete Remission | 203 of 296 | 207 of 300 | 596 | NCT00085709 | Trial comparisons |
Quizartinib vs Placebo: Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 54 of 268 | 51 of 271 | 539 | NCT02668653 | Trial comparisons |
| Quizartinib vs Placebo: Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 147 of 268 | 150 of 271 | 539 | NCT02668653 | Trial comparisons |
| Quizartinib vs Placebo: Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 192 of 268 | 176 of 271 | 539 | NCT02668653 | Trial comparisons |
Quizartinib vs Placebo: Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 66 of 268 | 58 of 271 | 539 | NCT02668653 | Trial comparisons |
| Quizartinib vs Placebo: deaths from any cause | 130 of 265 | 156 of 268 | 533 | NCT02668653 | Trial comparisons |
| Quizartinib vs Placebo: serious adverse events | 146 of 265 | 124 of 268 | 533 | NCT02668653 | Trial comparisons |
| Azacitidine (AZA) vs Conventional Care Regimens (CCR): Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC. | 5 of 241 | 15 of 247 | 488 | NCT01074047 | Trial comparisons |
| Sapacitabine-decitabine Alternating vs Decitabine: 1-year Survival | 81 of 241 | 83 of 241 | 482 | NCT01303796 | Trial comparisons |
| Cytarabine or Supportive Care vs Dacogen (Decitabine) Only: serious adverse events | 162 of 237 | 190 of 238 | 475 | NCT00260832 | Trial comparisons |
| Oral Azacitidine Plus Best Supportive Care vs Placebo Plus Best Supportive Care: deaths from any cause | 172 of 238 | 176 of 234 | 472 | NCT01757535 | Trial comparisons |
| Oral Azacitidine Plus Best Supportive Care vs Placebo Plus Best Supportive Care: serious adverse events | 110 of 236 | 109 of 233 | 469 | NCT01757535 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018874/comparisons